Short answer
Alector, Inc. (ALEC) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Genentech receives exclusive worldwide AL050 GCase rights, assuming development, regulatory, manufacturing, and commercialization responsibilities.
Alector, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Genentech receives exclusive worldwide AL050 GCase rights, assuming development, regulatory, manufacturing, and commercialization responsibilities
- Alector receives $100 million upfront, plus up to $1.17 billion in development, regulatory, and commercial milestones
- Alector retains its Brain Carrier platform and rights outside GCase programs, preserving broader pipeline flexibility
- Alector exercised Spur’s GCase patent option, paying $15 million plus teens-percentage sharing of sublicense income and royalty proceeds
- Genentech’s convenience termination right and Alector’s GCase restrictions create execution and strategic-risk considerations
Item 2.02 · Results of Operations and Financial Condition
- Preliminary September 30 liquidity: $138.7 million in cash, equivalents, and marketable securities
- Pro forma liquidity: $223.7 million after Genentech initial payments and Spur Agreement outflows
- Management expects funding runway into 2029, reducing near-term financing risk
- Figures remain unaudited and subject to change after quarter-end close procedures
Item 7.01 · Regulation FD Disclosure
- Alector issued a press release under Regulation FD, indicating disclosure of material investor information
- Exhibit 99.1 contains the substantive announcement requiring review for financial or strategic implications
Item EX-99.1 · Exhibit EX-99.1
- Exclusive global AL050 license to Genentech, transferring development, regulatory, manufacturing, and commercialization responsibility
- $100 million upfront payment, plus up to $1.17 billion in development, regulatory, and commercial milestones
- Tiered royalties on net sales, creating potential long-term revenue participation without commercialization costs
- Agreement extends Alector’s cash runway into 2029, funding wholly owned Alzheimer’s and Parkinson’s pipeline programs
- Alector retains ABC platform ownership and rights for its wholly owned pipeline, preserving broader strategic optionality
Other items in this filing:
- Item 8.01: Other Events
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alector, Inc. 8-K filings
Get the next ALEC 8-K as it lands
Follow ALEC for push alerts, or ask the research agent what this filing means.